drugset
drugset / Trial / NCT02022644

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma

NCT02022644 ↗

Phase 1 Completed 18 enrolled University of California, San Francisco Ipsen · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single center, dose-toleration study designed to investigate and determine the maximum tolerated dose of nanoliposomal irinotecan in adults with recurrent high-grade glioma when administered directly into the tumor using a process called convection-enhanced delivery (CED).

Timeline

Start
2014-10-23
Primary completion
2020-12-31
Completion
2023-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Nanoliposomal Irinotecan Unknown 20 mg Other
Subject Nanoliposomal Irinotecan Unknown 40 mg Other
Subject Nanoliposomal Irinotecan Unknown 80 mg Other
Subject Nanoliposomal Irinotecan Unknown 140 mg Other
Subject Nanoliposomal Irinotecan Unknown 280 mg Other
Subject Nanoliposomal Irinotecan Unknown 340 mg Other
Subject Nanoliposomal Irinotecan Unknown 680 mg Other

Indications

malignant glioma